KRAS Mutation in PDAC: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Meichen Gu and Version 5 by Lindsay Dong.

The vast majority of patients with pancreatic ductal adenocarcinomas harbor KRAS mutations in their tumors. Functionally, mutated KRAS is not only dedicated to tumor cell proliferation, survival and invasiveness, but also causing the immunosuppression in this cancer. 

  • KRAS gene
  • pancreatic ductal adenocarcinoma
  • cancer immunity
  • immune checkpoint blockade
Please wait, diff process is still running!

References

  1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424.Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [CrossRef]
  2. Vincent, A.; Herman, J.; Schulik, R.; Hruban, R.H.; Goggins, M. Pancreatic cancer. Lancet 2011, 378, 607–620.Vincent, A.; Herman, J.; Schulik, R.; Hruban, R.H.; Goggins, M. Pancreatic cancer. Lancet 2011, 378, 607–620. [CrossRef]
  3. Sohal, D.P.; Kennedy, E.B.; Cinar, P.; Conroy, T.; Copur, M.S.; Crane, C.H.; Garrido-Laguna, I.; Lau, M.W.; Johnson, T.; Krishnamurthi, S.; et al. Metastatic Pancreatic Cancer: ASCO Guideline Update. J. Clin. Oncol. 2020, 27, 3217–3230.Sohal, D.P.; Kennedy, E.B.; Cinar, P.; Conroy, T.; Copur, M.S.; Crane, C.H.; Garrido-Laguna, I.; Lau, M.W.; Johnson, T.; Krishnamurthi, S.; et al. Metastatic Pancreatic Cancer: ASCO Guideline Update. J. Clin. Oncol. 2020, 27, 3217–3230. [CrossRef][PubMed]
  4. Marabelle, A.; Le, D.T.; Ascierto, P.A.; di Giacomo, A.M.; de Jesus-Acosta, A.; Delord, J.P.; Geva, R.; Gottfried, M.; Penel, N.; Hansen, A.R.; et al. Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results from the Phase II KEYNOTE-158 Study. J Clin. Oncol. 2020, 38, 1–10.Marabelle, A.; Le, D.T.; Ascierto, P.A.; di Giacomo, A.M.; de Jesus-Acosta, A.; Delord, J.P.; Geva, R.; Gottfried, M.; Penel, N.; Hansen, A.R.; et al. Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results from the Phase II KEYNOTE-158 Study. J Clin. Oncol. 2020, 38, 1–10. [CrossRef] [PubMed]
  5. Henriksen, A.; Dyhl-Polk, A.; Chen, I.; Nielsen, D. Checkpoint inhibitors in pancreatic cancer. Cancer Treat. Rev. 2019, 78, 17–30.Henriksen, A.; Dyhl-Polk, A.; Chen, I.; Nielsen, D. Checkpoint inhibitors in pancreatic cancer. Cancer Treat. Rev. 2019, 78, 17–30. [CrossRef] [PubMed]
  6. Ribas, A.; Wolchok, J.D. Cancer immunotherapy using checkpoint blockade. Science 2018, 359, 1350–1355.Ribas, A.;Wolchok, J.D. Cancer immunotherapy using checkpoint blockade. Science 2018, 359, 1350–1355. [CrossRef] [PubMed]
  7. Liu, X.; Xu, J.; Zhang, B.; Liu, J.; Liang, C.; Meng, Q.; Hua, J.; Yu, X.; Shi, S. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: New insights and therapeutic implications. Mol. Cancer. 2019, 18, 184.Liu, X.; Xu, J.; Zhang, B.; Liu, J.; Liang, C.; Meng, Q.; Hua, J.; Yu, X.; Shi, S. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: New insights and therapeutic implications. Mol. Cancer. 2019, 18, 184. [CrossRef] [PubMed]
  8. Wellenstein, M.D.; de Visser, K.E. Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape. Immunity 2018, 48, 399–416.Wellenstein, M.D.; de Visser, K.E. Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape. Immunity 2018, 48, 399–416. [CrossRef]
  9. Cox, A.D.; Fesik, S.W.; Kimmelman, A.C.; Luo, J.; Der, C.J. Drugging the undruggable RAS: Mission possible? Nat. Rev. Drug Discov. 2014, 13, 828–851.Cox, A.D.; Fesik, S.W.; Kimmelman, A.C.; Luo, J.; Der, C.J. Drugging the undruggable RAS:Mission possible? Nat. Rev. Drug Discov. 2014, 13, 828–851. [CrossRef]
  10. Bailey, P.; Chang, D.K.; Nones, K.; Johns, A.L.; Patch, A.M.; Gingras, M.C.; Miller, D.K.; Christ, A.N.; Bruxner, T.J.; Quinn, M.C.; et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016, 531, 47–52.[10] Bailey P., Chang D. K. Nones K., Johns A. L., Patch A. M. Gingras M. C., et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016, 531: 47-52.
  11. Kamisawa, T.; Wood, L.D.; Itoi, T.; Takaori, K. Pancreatic cancer. Lancet 2016, 388, 73–85.[11] Kamisawa T., Wood L. D. Itoi T., Takaori K. Pancreatic cancer. Lancet. 2016, 388:73-85.
  12. Gruber, R.; Panayiotou, R.; Nye, E.; Spencer-Dene, B.; Stamp, G.; Behrens, A. YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling. Gastroenterology 2016, 151, 526–539.[12] Gruber R., Panayiotou R., Nye E., Spencer-Dene B., Stamp G., Behrens A. YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling. Gastroenterology. 2016, 151:526-39.
  13. Humpton, T.J.; Alagesan, B.; deNicola, G.M.; Lu, D.; Yordanov, G.N.; Leonhardt, C.S.; Yao, M.A.; Alagesan, P.; Zaatari, M.N.; Park, Y.; et al. Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer. Cancer Discov. 2019, 9, 1268–1287.[13] Humpton T. J., Alagesan B., DeNicola G. M., Lu D., Yordanov G. N. Leonhardt C. S., et al. Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer. Cancer Discov. 2019, 9:1268-1287.
  14. Yamamoto, K.; Venida, A.; Yano, J.; Biancur, D.E.; Kakiuchi, M.; Gupta, S.; Sohn, A.S.; Mukhopadhyay, S.; Lin, E.Y.; Parker, S.J.; et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature 2020, 581, 100–105.[14] Yamamoto K., Venida A., Yano J., Biancur D. E., Kakiuchi M., Gupta S., et al. Autophagy promotes immune evasion of pancre-atic cancer by degrading MHC-I. Nature. 2020, 581:100-105.
  15. Blagih, J.; Zani, F.; Chakravarty, P.; Hennequart, M.; Pilley, S.; Hobor, S.; Hock, A.K.; Walton, J.B.; Morton, J.P.; Gronroos, E.; et al. Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses. Cell Rep. 2020, 30, 481–496.[15] Blagih J., Zani F., Chakravarty P., Hennequart M., Pilley S., Hobor S., et al. Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses. Cell Rep. 2020, 30:481-496.
  16. Dong, Z.Y.; Zhong, W.Z.; Zhang, X.C.; Su, J.; Xie, Z.; Liu, S.Y.; Tu, H.Y.; Chen, H.J.; Sun, Y.L.; Zhou, Q.; et al. Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin. Cancer Res. 2017, 23, 3021–3024.[16] Dong Z.Y., Zhong W. Z., Zhang X. C., Su J., Xie Z., Liu S. Y., et al. Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2017, 23:3021-3024.
  17. Skoulidis, F.; Goldberg, M.E.; Greenawalt, D.M.; Hellmann, M.D.; Awad, M.M.; Gainor, J.F.; Schrock, A.B.; Hartmaier, R.J.; Trabucco, S.E.; Gay, L.; et al. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 2018, 8, 822–835.[17] Skoulidis F., Goldberg M. E., Greenawalt D. M., Hellman M. D. Awad M. M. Gainor J. F. et al. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 2018, 8:822-835.
  18. Liang, T.; Tong, W.; Ma, S.; Chang, P. Standard therapies: Solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer. OncoImmunology 2020, 9, 1773205.[18] Liang T., Tong W., Ma S., Chang P. Standard therapies: solutions for improving therapeutic effects of immune checkpoint in-hibitors on colorectal cancer. OncoImmunology. 2020, 9:1773205.
  19. Waters, A.M.; Der, C.J. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb. Perspect. Med. 2018, 8, a0311435.[19] Waters A. M., Der C. J. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med. 2018, 8: a0311435.
  20. Yun, J.; Rago, C.; Cheong, I.; Pagliarini, R.; Angenendt, P.; Rajagopalan, H.; Schmidt, K.; Willson, J.K.; Markowitz, S.; Zhou, S.; et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009, 325, 1555–1559.[20] He P., Yang J. W., Yang V. W., Bialkowska. A. B. Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Pro-motes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice. Gastroen-terology. 2018, 154: 1494-1508.
  21. Kerr, E.M.; Gaude, E.; Turrell, F.K.; Frezza, C.; Martins, C.P. Mutant KRAS copy number defines metabolic reprogramming and therapeutic susceptibilities. Nature 2016, 531, 110–113.[21] Zhang W., Nandakumar N., Shi Y., Manzano M., Smith A., Graham G., et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal. 2014, 7:ra42.
  22. Vakiani, E.; Janakiraman, M.; Shen, R.; Sinha, R.; Zeng, Z.; Shia, J.; Cercek, A.; Kemeny, N.; D’Angelica, M.; Viale, A.; et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J. Clin. Oncol. 2012, 30, 2956–2962.[22] DeNicola G. M., Karreth F. A., Humpton T. J., Gopinathan A., Wei C., Frese K., Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011, 475:106-9.
  23. Gu, M.; Xu, T.; Chang, P. KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas. Ther. Adv. Med. Oncol. 2020.[23] Chang C., Qiu J., O’Sullivan D., Buck M. D. Noguchi T., Curtis J. D., et al. Metabolic Competition in the Tumor Microenviron-ment Is a Driver of Cancer Progression. Cell. 2015, 162:1229-41.
  24. Lal, N.; White, B.S.; Goussous, G.; Pickles, O.; Mason, M.J.; Beggs, A.D.; Taniere, P.; Willcox, B.E.; Guinney, J.; Middleton, G.W. KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer. Clin. Cancer Res. 2018, 24, 224–233.[24] Kottakis F., Nicolay B. N., Roumane A., Karnik R., Gu H., Nagle J. M., et al. LKB loss links serine metabolism to DNA methyla-tion and tumorigenesis. Nature. 2016, 539: 390-395.
  25. Luchini, C.; Brosens, L.A.A.; Wood, L.D.; Chatterjee, D.; Shin, J., II; Sciammarella, C.; Fiadone, G.; Malleo, G.; Salvia, R.; Kryklyva, V.; et al. Comprehensive characterization of pancreatic ductal adenocarcinoma with microsatellite instability: Histology, molecular pathology and clinical implications. Gut 2020, 70, 148–156.[25] Jones S. A., Jenkins B. J. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018, 18:773-789.
  26. Guinney, J.; Dienstmann, R.; Wang, X.; de Reynies, A.; Schlicker, A.; Soneson, C.; Marisa, L.; Roepman, P.; Nyamundanda, G.; Angelino, P.; et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 2015, 21, 1350–1356.[26] Corcoran R. B., Contino G., Deshpande V., Tzatsos A., Conrad C., Benes C. H. et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 2011, 71:5020-9.
  27. Andre, T.; Shiu, K.K.; Kim, T.W.; Jensen, B.V.; Jensen, L.H.; Punt, C.; Smith, D.; Garcia-Carbonero, R.; Benavides, M.; Gibbs, P.; et al. KEYNOTE-177: Phase 3, Open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC). J. Clin. Oncol. 2018, 36.[27] Eibl G., Rozengurt E. KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops. Semin Cancer Biol. 2019, 54: 50-62.
  28. Ganesh, K.; Stadler, Z.K.; Cercek, A.; Mendelsohn, R.B.; Shia, J.; Segal, N.H.; Diaz, L.A. Immunotherapy in colorectal cancer: Rationale, challenges and potential. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 361–375.[28] Zhao X., Wang X., Fang L., Lan C., Zheng X., Wang Y., et al. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer. Cancer Lett. 2017, 402: 61-70.
  29. Gan, L.L.; Hii, L.W.; Wong, S.F.; Leong, C.O.; Mai, C.W. Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion. Cancers 2020, 12, 1872.[29] Allende M., Zeron-Medina J., Hernandez J., Macarulla T., Balsells J., Merino X., et al. Overexpression of Yes Associated Protein 1, an Independent Prognostic Marker in Patients With Pancreatic Ductal Adenocarcinoma, Correlated With Liver Metastasis and Poor Prognosis. Pancreas. 2017, 46:913-920.
  30. Sivaram, N.; McLaughlin, P.A.; Han, H.V.; Petrenko, O.; Jiang, Y.P.; Ballou, L.M.; Pham, K.; Liu, C.; van der Velden, A.W.; Lin, R.Z. Tumor-intrinsic PIK3CA represses tumor immunogenecity in a model of pancreatic cancer. J. Clin. Investig. 2019, 129, 3264–3276.[30] Yang W., Yang S., Zhang F., Cheng F., Wang X., Rao J. Influence of the Hippo-YAP signaling pathway on tumor associated macrophages (TAMs) and its implications on cancer immunosuppressive microenvironment. Ann Transl Med. 2020, 8:399.
  31. Boutin, A.T.; Liao, W.T.; Wang, M.; Hwang, S.S.; Karpinets, T.V.; Cheung, H.; Chu, G.C.; Jiang, S.; Hu, J.; Chang, K.; et al. Oncogenic KRAS drives invasion and maintains metastases in colorectal cancer. Genes Dev. 2017, 31, 370–382.[31] Hingorani S. R., Wang L., Multani A. S., Combs C., Deramaudt T. B. Hruban R. H., et al. Trp53R172H and KRASG12D cooper-ate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005, 7:469-83.
  32. Yoshimura, A.; Muto, G. TGF-β function in immune suppression. Curr. Top Microbiol. Immunol. 2011, 350, 127–147.[32] Murakami S., Shabhazian D., Surana R., Zhang W., Chen H., Graham G. T., Yes-associated protein mediates immune repro-gramming in pancreatic ductal adenocarcinoma. Oncogene. 2017, 36:1232-1244.
  33. Liao, W.; Overman, M.J.; Boutin, A.T.; Shang, X.; Zhao, D.; Dey, P.; Li, J.; Wang, G.; Lan, Z.; Li, J.; et al. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell. 2019, 35, 559–572.[33] Gan L. L., Hii L.W., Wong S. F., Leong C. O., Mai C. W. Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion. Cancers (Basel). 2020, 12:1872.
  34. Wang, G.; Wang, J.J.; Yin, P.H.; Xu, K.; Wang, Y.Z.; Shi, F.; Gao, J.; Fu, X.L. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy. J. Cell Physiol. 2019, 234, 5601–5612.[34] Sivaram N., McLaughlin P. A., Han H. V., Petrenko O., Jiang Y. P., Ballou L. M., et al. Tumor-intrinsic PIK3CA represses tumor immunogenecity in a model of pancreatic cancer. J Clin Invest. 2019, 129:3264-3276.
  35. He, P.; Yang, J.W.; Yang, V.W.; Bialkowska, A.B. Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice. Gastroenterology 2018, 154, 1494–1508.[35] Fukumura D., Kloepper J., Amoozgar Z., Duda D. G., Jain R. K. Enhancing cancer immunotherapy using antiangiogenics: op-portunities and challenges. Nat Rev Clin Oncol. 2018, 15:325-340.
  36. Zhang, W.; Nandakumar, N.; Shi, Y.; Manzano, M.; Smith, A.; Graham, G.; Gupta, S.; Vietsch, E.E.; Laughlin, S.Z.; Wadhwa, M.; et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci. Signal. 2014, 7, ra42.[36] Li S., Xu H. X., Wu C. T., Wang W. Q., Jin W., Gao H. L., et al. Angiogenesis in pancreatic cancer: current research status and clinical implications. Angiogenesis. 2019, 22:15-36.
  37. De Nicola, G.M.; Karreth, F.A.; Humpton, T.J.; Gopinathan, A.; Wei, C.; Frese, K. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011, 475, 106–109.[37] Sodir N.M., Kortlever R. M., Barthet V. J. A., Campos T., Pellegrinet L., Kupczak S., et al. MYC Instructs and Maintains Pancre-atic Adenocarcinoma Phenotype. Cancer Discov. 2020, 10:588-607.
  38. Chang, C.; Qiu, J.; O’Sullivan, D.; Buck, M.D.; Noguchi, T.; Curtis, J.D.; Chen, Q.; Gindin, M.; Gubin, M.M.; van der Windt, G.J.; et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell 2015, 162, 1229–1241.[38] Lu C., Paschall A. V., Shi H., Savage N., Waller J.L., Sabbatini M. E., et al. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expres-sion and Pancreatic Cancer Immune Evasion. J. Natl. Cancer Inst. 2017, 109: djw283.
  39. Kottakis, F.; Nicolay, B.N.; Roumane, A.; Karnik, R.; Gu, H.; Nagle, J.M.; Boukhali, M.; Hayward, M.C.; Li, Y.Y.; Chen, T.; et al. LKB loss links serine metabolism to DNA methylation and tumorigenesis. Nature 2016, 539, 390–395.[39] Johnson B. A. 3rd., Yarchoan M., Lee V., Laheru D. A., Jaffee E. M. Strategies for Increasing Pancreatic Tumor Immunogenicity. Clin Cancer Res. 2017, 23:1656-1669.
  40. Jones, S.A.; Jenkins, B.J. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat. Rev. Immunol. 2018, 18, 773–789.[40] Joyce J. A., Fearon D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015, 348: 74-80.
  41. Corcoran, R.B.; Contino, G.; Deshpande, V.; Tzatsos, A.; Conrad, C.; Benes, C.H.; Levy, D.E.; Settleman, J.; Engelman, J.A.; Bardeesy, N. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 2011, 71, 5020–5029.[41] Feig C., Jones J. O., Kraman M., Wells R. J. B., Deonarine A., Chan D. S., Targeting CXCL12 from FAP-expressing carcino-ma-associated fibroblasts synergized with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013, 110: 20212-7.
  42. Eibl, G.; Rozengurt, E. KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops. Semin. Cancer Biol. 2019, 54, 50–62.[42] Beatty G. L., Winograd R., Evans R. A., Long K. B., Luque S. L., Lee J. W., et al. Exclusion of T cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extracuumoral Macrophages. Gastroenterology. 2015, 149:201-10.
  43. Zhao, X.; Wang, X.; Fang, L.; Lan, C.; Zheng, X.; Wang, Y.; Zhang, Y.; Han, X.; Liu, S.; Cheng, K.; et al. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer. Cancer Lett. 2017, 402, 61–70.[43] O’Reilly E.M., Oh D.Y., Dhani N., Renouf D.J. Lee M. A., Sun W., et al. Durvalumab With or Without Tremelimumab for Pa-tients With Metastatic Pancreatic Ductal Adenocarcinoma: A phase 2 Randomized Clinical Trial. JAMA Oncol. 2019, 5: 1431-8.
  44. Allende, M.T.S.; Zeron-Medina, J.; Hernandez, J.; Macarulla, T.; Balsells, J.; Merino, X.; Allende, H.; Tabernero, J. Overexpression of Yes Associated Protein 1, an Independent Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma, Correlated with Liver Metastasis and Poor Prognosis. Pancreas 2017, 46, 913–920.[44] Luke J.J., Lemons J.M., Karrison T. G., Pitroda S.P., Melotek J. M., Zha Y. Y., et al. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018, 36:1611-1618.
  45. Yang, W.; Yang, S.; Zhang, F.; Cheng, F.; Wang, X.; Rao, J. Influence of the Hippo-YAP signaling pathway on tumor associated macrophages (TAMs) and its implications on cancer immunosuppressive microenvironment. Ann. Transl. Med. 2020, 8, 399.[45] Xie C., Duffy A. G., Brar G., Fioravanti S., Mabry-Hrones D., Walker M., et al. Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2020, 26:2318-2326.
  46. Hingorani, S.R.; Wang, L.; Multani, A.S.; Combs, C.; Deramaudt, T.B.; Hruban, R.H.; Rustgi, A.K.; Chang, S.; Tuveson, D.A. Trp53R172H and KRASG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005, 7, 469–483.[46] Wang Q., Ju X., Wang J., Fan Y., Ren M., Zhang H. Immunogenic cell death in anticancer chemotherapy and its impact on clini-cal studies. Cancer Lett. 2018, 438: 17-23.
  47. Murakami, S.; Shabhazian, D.; Surana, R.; Zhang, W.; Chen, H.; Graham, G.T. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. Oncogene 2017, 36, 1232–1244.[47] Weiss G. J., Waypa J., Blaydorn L., Coats J., McGahey K., Sangal A., et al. A phase Ib study of pembrolizumab plus chemother-apy in patients with advanced cancer (PmebroPlus). Br J Cancer. 2017, 117:33-40.
  48. Fukumura, D.; Kloepper, J.; Amoozgar, Z.; Duda, D.G.; Jain, R.K. Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges. Nat. Rev. Clin. Oncol. 2018, 15, 325–340.[48] Kamath S. D., Kalyan A., Kircher S., Nimeiri H., Fought A.J., Benson 3rd Al., et al. Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A phase Ib Study. Oncologist. 2020, 25: e808-e815.
  49. Li, S.; Xu, H.X.; Wu, C.T.; Wang, W.Q.; Jin, W.; Gao, H.L.; Li, H.; Zhang, S.R.; Xu, J.Z.; Qi, Z.H.; et al. Angiogenesis in pancreatic cancer: Current research status and clinical implications. Angiogenesis 2019, 22, 15–36.[49] Dawood S., Austin L., Cristofanilli M. Cancer stem cells: implications for cancer therapy. Oncology (Williston Park). 2014, 28:1101-7.
  50. Sodir, N.M.; Kortlever, R.M.; Barthet, V.J.; Campos, T.; Pellegrinet, L.; Kupczak, S.; Anastasiou, P.; Swigart, L.B.; Soucek, L.; Arends, M.J.; et al. MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype. Cancer Discov. 2020, 10, 588–607.[50] Riaz N., Havel J. J., Makarov V., Desrichard A., Urba W. J., Sims J. S., et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017, 171: 934-949.
  51. Lu, C.; Paschall, A.V.; Shi, H.; Savage, N.; Waller, J.L.; Sabbatini, M.E.; Oberlies, N.H.; Pearce, C.; Liu, K. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion. J. Natl. Cancer Inst. 2017, 109, djw283.[51] Conroy T., Desseigne F., Ychou M., Bouché O., Guimbaud R., Bécouarn Y., et al. FOLFIRINOX versus gemcitabine for meta-static pancreatic cancer. N Engl J Med. 2011, 364:1817-25.
  52. Johnson, B.A., III; Yarchoan, M.; Lee, V.; Laheru, D.A.; Jaffee, E.M. Strategies for Increasing Pancreatic Tumor Immunogenicity. Clin. Cancer Res. 2017, 23, 1656–1669.[52] Von Hoff D. D., Ervin T., Arena F. P., Chiorean E. G., Infante J., Moore M., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013, 369:1691-703.
  53. Joyce, J.A.; Fearon, D.T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015, 348, 74–80.[53] Schumacher T.N., Scheper W., Kvistborg P. Cancer Neoantigens. Annu Rev Immunol. 2019, 37:173-200.
  54. Feig, C.; Jones, J.O.; Kraman, M.; Wells, R.J.B.; Deonarine, A.; Chan, D.S. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergized with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. USA 2013, 110, 20212–20217.[54] Aglietta M., Barone C., Sawyer M. B., Moore M. J., Miller Jr W. H., Bagalà C., et al. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Ann Oncol. 2014, 25:1750-5.
  55. Beatty, G.L.; Winograd, R.; Evans, R.A.; Long, K.B.; Luque, S.L.; Lee, J.W.; Clendenin, C.; Gladney, W.L.; Knoblock, D.M.; Guirnalda, P.D.; et al. Exclusion of T cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extracuumoral Macrophages. Gastroenterology 2015, 149, 201–210.[55] Wainberg Z. A., Hochster H.S., Kim E., George B., Kalyan A., Chiorean E.G., et al. Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) + gemcitabine (Gem) in advanced pancreatic cancer (APC). J Clin Oncol. 2019, 37:298.
  56. O’Reilly, E.M.; Oh, D.Y.; Dhani, N.; Renouf, D.J.; Lee, M.A.; Sun, W.; Fisher, G.; Hezel, A.; Chang, S.C.; Vlahovic, G.; et al. Durvalumab With or Without Tremelimumab for Patients with Metastatic Pancreatic Ductal Adenocarcinoma: A phase 2 Randomized Clinical Trial. JAMA Oncol. 2019, 5, 1431–1438.[56] Wainberg Z. A., Hochster H. S., George B., Gutierrez M., Johns M. E., Chiorean E. G., et al. Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) ± gemcitabine (Gem) in solid tumors: interim results from the pancreatic cancer (PC) cohorts [abstracts]. J Clin Oncol. 2017, 35: 412.
  57. Luke, J.J.; Lemons, J.M.; Karrison, T.G.; Pitroda, S.P.; Melotek, J.M.; Zha, Y.; Al-Hallaq, H.A.; Arina, A.; Khodarev, N.N.; Janisch, L.; et al. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients with Advanced Solid Tumors. J. Clin. Oncol. 2018, 36, 1611–1618.[57] Renouf D.J., Dhani N.C., Kavan P., Jonker D.J., Wei AC-C., Hsu T., et al. The Canadian Cancer Trials Group PA.7 trial: results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC). J Clin Oncol. 2018, 36: 349.
  58. Xie, C.; Duffy, A.G.; Brar, G.; Fioravanti, S.; Mabry-Hrones, D.; Walker, M.; Bonilla, C.M.; Wood, B.J.; Citrin, D.E.; Ramirez, E.M.G.; et al. Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clin. Cancer Res. 2020, 26, 2318–2326.[58] Borazanci E.H., Jameson G.S., Borad M.J., Ramanathan R.K., Korn R.L., Caldwell L., et al. A phase II pilot trial of nivolumab (N) + albumin bound paclitaxel (AP) + paricalcitol (P) + cisplatin (C) + gemcitabine (G) (NAPPCG) in patients with previously un-treated metastatic pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2018, 36:358.
  59. Wang, Q.; Ju, X.; Wang, J.; Fan, Y.; Ren, M.; Zhang, H. Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies. Cancer Lett. 2018, 438, 17–23.[59] Luchini C., Brosens L. A. A., Wood L. D. Chatterjee D., Shin J. II., Sciammarella C., et al. Comprehensive characterization of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Gut. 2020. Online ahead of print.
  60. Weiss, G.J.; Waypa, J.; Blaydorn, L.; Coats, J.; McGahey, K.; Sangal, A.; Niu, J.; Lynch, C.A.; Farley, J.H.; Khemka, V. A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PmebroPlus). Br. J. Cancer 2017, 117, 33–40.[60] Allen E., Jabouille A., Rivera Lee B., Lodewijckx I., Missiaen R., Steri V., et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates immunity through HEV formation. Sci Transl Med. 2017, 9: eaak9679.
  61. Kamath, S.D.; Kalyan, A.; Kircher, S.; Nimeiri, H.; Fought, A.J.; Benson, A., III; Mulcahy, M. Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A phase Ib Study. Oncologist 2020, 25, e808–e815.[61] Mace T. A., Shakya R., Pitaarresi J. R., Swanson B., McQuinn C. W., Loftus S., et al. IL-6 and PD-L1 antibody blockade combina-tion therapy reduces tumour progression in murine models of pancreatic cancer. Gut. 2018, 67:320-332.
  62. Aglietta, M.; Barone, C.; Sawyer, M.B.; Moore, M.J.; Miller, W.H., Jr.; Bagalà, C.; Colombi, F.; Cagnazzo, C.; Gioeni, L.; Wang, E.; et al. A phase I dose, escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Ann. Oncol. 2014, 25, 1750–1755.[62] Zhang Q., Green M. D., Lang X., Lazarus J., Parsels J. D., Wei S., Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. Cancer Res. 2019, 79:3940-3951.
  63. Wainberg, Z.A.; Hochster, H.S.; George, B.; Gutierrez, M.; Johns, M.E.; Chiorean, E.G.; Kwak, E.L.; Kalyan, A.; Manax, V.; Ye, M.; et al. Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) + gemcitabine (Gem) in advanced pancreatic cancer (APC). J. Clin. Oncol. 2019, 37, 298.[63] Zhu Y., Knolhoff B.L., Meyer M.A., Nywening T.M., West B.L., Luo J., et al. CSF1/CSF1R blockade reprograms tu-mor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014, 74:5057-69.
  64. Wainberg, Z.A.; Hochster, H.S.; George, B.; Gutierrez, M.; Johns, M.E.; Chiorean, E.G.; Kwak, E.L.; Kalyan, A.; Manax, V.; Ye, M.; et al. Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) ± gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts. J. Clin. Oncol. 2017, 35, 412.[64] Stewart R. A., Pilié P.G., Yap T. A. Development of PARP and Immune-Checkpoint Inhibitor Combinations. Cancer Res. 2018, 78: 6717-6725.
  65. Renouf, D.J.; Dhani, N.C.; Kavan, P.; Jonker, D.J.; Wei, A.C.C.; Hsu, T.; Tang, P.A.; Graham, B.; Gallinaro, L.; Hasan, T.; et al. The Canadian Cancer Trials Group PA.7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC). J. Clin. Oncol. 2018, 36, 349.[65] Keenan B. P., Saenger Y., Kafrouni M. I., Leubner A., Lauer P., Maitra A., et al. A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. Gastroenterology. 2014, 146: 1784-94.
  66. Borazanci, E.H.; Jameson, G.S.; Borad, M.J.; Ramanathan, R.K.; Korn, R.L.; Caldwell, L.; Ansaldo, K.; Hendrickson, K.; Marceau, K.; von Hoff, D.D. A phase II pilot trial of nivolumab (N) + albumin bound paclitaxel (AP) + paricalcitol (P) + cisplatin (C) + gemcitabine (G) (NAPPCG) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC). J. Clin. Oncol. 2018, 36, 358.[66] Jiang H., Hegde S., Knolhoff B. L., Zhu Y., Herndon J. M., Meyer M. A., et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016, 22:851-60.
  67. Dawood, S.; Austin, L.; Cristofanilli, M. Cancer stem cells: Implications for cancer therapy. Oncology 2014, 28, 1101–1107.[67] Sanford D. E., Belt B. A., Panni R. Z., Mayer A., Deshpande A. D., Carpenter D., et al. Inflammatory monocyte mobilization de-creases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res. 2013, 19:3404-15.
  68. Riaz, N.; Havel, J.J.; Makarov, V.; Desrichard, A.; Urba, W.J.; Sims, J.S.; Hodi, F.S.; Martín-Algarra, S.; Mandal, R.; Sharfman, W.H.; et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell 2017, 171, 934–949.[68] Blair A.B., Kleponis J., Thomas D.L. 2nd., Muth S. T., Murphy A. G., Kim V., et al. IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma. J Clin Invest. 2019, 129:1742-1755.
  69. Conroy, T.; Desseigne, F.; Ychou, M.; Bouché, O.; Guimbaud, R.; Bécouarn, Y.; Adenis, A.; Raoul, J.L.; Gourgou-Bourgade, S.; de la Fouchardière, C.; et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011, 364, 1817–1825.[69] Burrack A. L., Spartz E. J., Raynor J. F., Wang I., Olson M., Stromnes I.M. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma. Cell Rep. 2019, 28:2140-2155.
  70. Von Hoff, D.D.; Ervin, T.; Arena, F.P.; Chiorean, E.G.; Infante, J.; Moore, M.; Seay, T.; Tjulandin, S.A.; Ma, W.W.; Saleh, M.N.; et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 2013, 369, 1691–1703.[70] Christenson E. S., Jaffee E., Azad N. S. Current and emerging therapies for patients with advanced pancreatic ductal adenocar-cinoma: a bright future. Lancet Oncol. 2020, 21: e135-e145.
  71. Schumacher, T.N.; Scheper, W.; Kvistborg, P. Cancer Neoantigens. Annu. Rev. Immunol. 2019, 37, 173–200.[71] Nollmann FI., Ruess DA. Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising? Biomedicines. 2020,8(8):281.
  72. Allen, E.; Jabouille, A.; Rivera, L.B.; Lodewijckx, I.; Missiaen, R.; Steri, V.; Feyen, K.; Tawney, J.; Hanahan, D.; Michael, I.P.; et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates immunity through HEV formation. Sci. Transl. Med. 2017, 9, eaak9679.[72] Canon J., Rex K., Saiki A.Y., Mohr C., Cooke K., Bagal D., et al. The clinical KRAS(G12C) inhibitor AMG510 drives anti-tumour immunity. Nature. 2019, 575(7781):217-223.
  73. Mace, T.A.; Shakya, R.; Pitarresi, J.R.; Swanson, B.; McQuinn, C.W.; Loftus, S.; Nordquist, E.; Cruz-Monserrate, Z.; Yu, L.; Young, G.; et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut 2018, 67, 320–332.[73] Hallin J., Engstrom L.D., Hargis L., Calinisan A., Aranda R., Briere D. M., et al. The KRASG12C Inhibitor MRTX849 Provides In-sight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discov. 2020, 10(1): 54-71.
  74. Zhang, Q.; Green, M.D.; Lang, X.; Lazarus, J.; Parsels, J.D.; Wei, S. Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. Cancer Res. 2019, 79, 3940–3951.[74] Hong D. S., Fakih M. G., Strickler J. H., Desai J., Durm G. A., Shapiro G.I., et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020, 383(13):1207-1217.
  75. Zhu, Y.; Knolhoff, B.L.; Meyer, M.A.; Nywening, T.M.; West, B.L.; Luo, J.; Wang-Gillam, A.; Goedegebuure, S.P.; Linehan, D.C.; DeNardo, D.G. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014, 74, 5057–5069.[75] Briere D., Calinisan A., Aranda R., Sudhakar N., Hargis L., Gatto S., The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Leads to Durable Complete Responses in Combination with Anti-PD-1 Therapy in a Syngeneic Mouse Model. AACR 2019. [Abstract]
  76. Stewart, R.A.; Pilié, P.G.; Yap, T.A. Development of PARP and Immune-Checkpoint Inhibitor Combinations. Cancer Res. 2018, 78, 6717–6725.[76] Tran E., Robbins P.F., Lu Y.C., Prickett T.D., Gartner J.J., Jia L., et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med. 2016, 375(23):2255-2262.
  77. Keenan, B.P.; Saenger, Y.; Kafrouni, M.I.; Leubner, A.; Lauer, P.; Maitra, A.; Rucki, A.A.; Gunderson, A.J.; Coussens, L.M.; Brockstedt, D.G.; et al. A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. Gastroenterology 2014, 146, 1784–1794.[77] Vakiani E., Janakiraman M., Shen R., Sinha R., Zeng Z., Shia J., et al. Comparative genomic analysis of primary versus meta-static colorectal carcinomas. J Clin Oncol. 2012, 30: 2956-2962.
  78. Jiang, H.; Hegde, S.; Knolhoff, B.L.; Zhu, Y.; Herndon, J.M.; Meyer, M.A.; Nywening, T.M.; Hawkins, W.G.; Shapiro, I.M.; Weaver, D.T.; et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat. Med. 2016, 22, 851–860.[78] Yoshimura A., Muto G. TGF-β function in immune suppression. Curr Top Microbiol Immunol. 2011, 350:127-47.
  79. Sanford, D.E.; Belt, B.A.; Panni, R.Z.; Mayer, A.; Deshpande, A.D.; Carpenter, D.; Mitchem, J.B.; Plambeck-Suess, S.M.; Worley, L.A.; Goetz, B.D.; et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: A role for targeting the CCL2/CCR2 axis. Clin. Cancer Res. 2013, 19, 3404–3415.[79] Boutin A. T., Liao W. T., Wang M., Hwang S. S., Karpinets T. V., Cheung H., et al. Oncogenic KRAS drives invasion and main-tains metastases in colorectal cancer. Genes Dev. 2017, 31:370-382.
  80. Blair, A.B.; Kleponis, J.; Thomas, D.L.; Muth, S.T.; Murphy, A.G.; Kim, V.; Zheng, L. IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma. J. Clin. Investig. 2019, 129, 1742–1755.[80] Smeby J., Sveen A., Merok M. A., Danielssen S. A., Eilertsen I. A., Guren M. G., et al. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. Ann Oncol. 2018, 29:1227-1234.
  81. Burrack, A.L.; Spartz, E.J.; Raynor, J.F.; Wang, I.; Olson, M.; Stromnes, I.M. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma. Cell Rep. 2019, 28, 2140–2155.[81] Guinney J., Dienstmannn R., Wang X., deReyniès A., Schlicker A., Soneson C., et al. The consensus molecular subtypes of colo-rectal cancer. Nat Med. 2015, 21:1350-6.
  82. Christenson, E.S.; Jaffee, E.; Azad, N.S. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: A bright future. Lancet Oncol. 2020, 21, e135–e145.[82] Le D. T., Kim T. W., Van Cutsem E., Geva R., Jäger D., Hara H., et al. Phase II Open-Label Study of Pembrolizumab in Treat-ment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2020, 38:11-19.
  83. Nollmann, F.I.; Ruess, D.A. Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising? Biomedicines 2020, 8, 281.[83] Overman M. J., Lonardi S., Wong K. Y. M., Lenz H. J., Gelsomino F., Aglietta M., et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018, 36:773-779.
  84. Canon, J.; Rex, K.; Saiki, A.Y.; Mohr, C.; Cooke, K.; Bagal, D.; Gaida, K.; Holt, T.; Knutson, C.G.; Koppada, N.; et al. The clinical KRAS(G12C) inhibitor AMG510 drives anti-tumour immunity. Nature 2019, 575, 217–223.[84] Andre T., Shiu K. K., Kim T. W., Jensen B. V., Jensen L. H., Punt C., et al. KEYNOTE-177: Phase 3, Open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC)[Abstract]. J Clin Oncol. 2018, 4-suppl (Feb-ruary 26th).
  85. Hallin, J.; Engstrom, L.D.; Hargis, L.; Calinisan, A.; Aranda, R.; Briere, D.M.; Sudhakar, N.; Bowcut, V.; Baer, B.R.; Ballard, J.A.; et al. The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discov. 2020, 10, 54–71.[85] Ganesh K., Stadler Z. K., Cercek A., Mendelsohn R. B., Shia J., Segal N. H., et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019, 16:361-375.
  86. Hong, D.S.; Fakih, M.G.; Strickler, J.H.; Desai, J.; Durm, G.A.; Shapiro, G.I.; Falchook, G.S.; Price, T.J.; Sacher, A.; Denlinger, C.S.; et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N. Engl. J. Med. 2020, 383, 1207–1217.[86] Lal N., White B. S., Goussous G., Pickles O., Mason M. J., Beggs A. D., et al. KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer. Clin Cancer Res. 2018, 24:224-233.
  87. Briere, D.; Calinisan, A.; Aranda, R.; Sudhakar, N.; Hargis, L.; Gatto, S. The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Leads to Durable Complete Responses in Combination with Anti-PD-1 Therapy in a Syngeneic Mouse Model. Mol. Cancer Ther. 2021.[87] Liao W., Overman M. J., Boutin A. T., Shang X., Zhao D., Dey P., et al. KRAS-IRF2 Axis Drives Immune Suppression and Im-mune Therapy Resistance in Colorectal Cancer. Cancer Cell. 2019, 35:559-572.
  88. Tran, E.; Robbins, P.F.; Lu, Y.C.; Prickett, T.D.; Gartner, J.J.; Jia, L.; Pasetto, A.; Zheng, Z.; Ray, S.; Groh, E.M.; et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N. Engl. J. Med. 2016, 375, 2255–2262.[88] Tran E., Ahmadzadeh M., Lu Y. C., Gros A., Turcotte S., Robbins P. F., et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015, 350:1387-90.
  89. Smeby, J.; Sveen, A.; Merok, M.A.; Danielsen, S.A.; Eilertsen, I.A.; Guren, M.G.; Dienstmann, R.; Nesbakken, A.; Lothe, R.A. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. Ann. Oncol. 2018, 29, 1227–1234.[89] Yuki S., et al. Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoper-ative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal can-cer. 2020 ASCO annual meeting. [Abstract 4100]
  90. Le, D.T.; Kim, T.W.; van Cutsem, E.; Geva, R.; Jager, D.; Hara, H.; Burge, M.; O’Neil, B.; Kavan, P.; Yoshino, T.; et al. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J. Clin. Oncol. 2020, 38, 11–19.[90] Ghiringhelli F., et al. Durvalumab and tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatel-lite-stable, previously untreated metastatic colorectal cancer (mCRC): Results of the first intermediate analysis of the phase Ib/II MEDETREME trial. J Clin Oncol. 2020 38: 15-suppl, 3006.
  91. Overman, M.J.; Lonardi, S.; Wong, K.Y.M.; Lenz, H.J.; Gelsomino, F.; Aglietta, M.; Morse, M.A.; van Cutsem, E.; McDermott, R.; Hill, A.; et al. Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J. Clin. Oncol. 2018, 36, 773–779.[91] Shota F., et al. Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). 2019 ASCO annual meeting. [Abstract]
  92. Tran, E.; Ahmadzadeh, M.; Lu, Y.C.; Gros, A.; Turcotte, S.; Robbins, P.F.; Gartner, J.J.; Zheng, Z.; Li, Y.F.; Ray, S.; et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 2015, 350, 1387–1390.[92] Wang G., Wang J. J., Yin P. H., Xu K., Wang Y. Z., Shi F., et al. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy. J Cell Physiol. 2019, 234:5601-5612.
  93. Yuki, S.; Bando, H.; Tsukada, Y.; Inamori, K.; Komatsu, Y.; Homma, S.; Uemura, M.; Kato, T.; Kotani, D.; Fukuoka, S.; et al. Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer. J. Clin. Oncol. 2020, 38, 4100.[93] Yun J., Rago C., Cheong I., Pagliarini R., Angenendt P., Rajagopalan H., et al. Glucose deprivation contributes to the develop-ment of KRAS pathway mutations in tumor cells. Science. 2009, 325: 1555-9.
  94. Ghiringhelli, F.; Chibaudel, B.; Taieb, J.; Bennouna, J.; Martin-Babau, J.; Fonck, M.; Borg, C.; Cohen, R.; Thibaudin, M.; Limagne, E.; et al. Durvalumab and tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatellite-stable, previously untreated metastatic colorectal cancer (mCRC): Results of the first intermediate analysis of the phase Ib/II MEDETREME trial. J. Clin. Oncol. 2020, 38, 3006.[94] Kerr E. M., Gaude E., Turrell F. K., Frezza C., Martins C. P. Mutant KRAS copy number defines metabolic reprogramming and therapeutic susceptibilities. Nature. 2016, 531: 110-3.
  95. Fukuoka, S.; Hara, H.; Takahashi, N.; Kojima, T.; Kawazoe, A.; Asayama, M.; Yoshii, T.; Kotani, D.; Tamura, H.; Mikamoto, Y.; et al. Regorafenib Plus Nivolumab in Patients with Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). J. Clin. Oncol. 2020, 38, 2053–2061.[95] Gu M., Xu T., Chang P. KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcino-mas. Ther Adv Med Oncol. 2020, ahead of print.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Feedback